Pfizer: positive results for eczema drug, chairman leaves
(CercleFinance.com) - On Friday Pfizer presented positive results from a second pivotal phase 3 study of its experimental drug abrocitinib in patients aged 12 and older suffering from moderate-to-severe atopic dermatitis.
Results showed that by week 12 the percentage of patients achieving each co-primary efficacy endpoint and each key secondary endpoint with either dose of abrocitinib was "statistically significantly higher" than placebo.
In addition, a statistically significant number of patients achieved a reduction in pruritus by week two, the US drugmaker said.
Pfizer also announced on Friday that the executive chairman of its board, Ian Read, has chosen to retire at the end of the year.
Its board has unanimously elected Pfizer's current CEO, Albert Bourla, to succeed him as chairman of the board of directors effective as of 1 January 2020. Bourla will also retain the CEO role.
Read joined Pfizer in 1978. He was named CEO of Pfizer in 2010, and chairman of the board in 2011.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Results showed that by week 12 the percentage of patients achieving each co-primary efficacy endpoint and each key secondary endpoint with either dose of abrocitinib was "statistically significantly higher" than placebo.
In addition, a statistically significant number of patients achieved a reduction in pruritus by week two, the US drugmaker said.
Pfizer also announced on Friday that the executive chairman of its board, Ian Read, has chosen to retire at the end of the year.
Its board has unanimously elected Pfizer's current CEO, Albert Bourla, to succeed him as chairman of the board of directors effective as of 1 January 2020. Bourla will also retain the CEO role.
Read joined Pfizer in 1978. He was named CEO of Pfizer in 2010, and chairman of the board in 2011.
Copyright (c) 2019 CercleFinance.com. All rights reserved.